Mechanistic modeling of tumor immune microenvironment reveals strategies to enhance antibody-drug conjugates efficacy
Background
Antibody-drug conjugates (ADCs) and bispecific antibodies represent a rapidly advancing frontier in oncology, yet the abnormal tumor microenvironment (TME) hinders their delivery and reduces efficacy. Emerging immunomodulatory ADCs (IM-ADCs…